跳至主要内容
临床试验/IRCT20090117001556N159
IRCT20090117001556N159尚未招募2 期

The effect of Rosiglitazone as an adjuvant therapy on the improvement of negative symptoms in patients with chronic schizophrenia: A randomized, double-blind, placebo-controlled trial

niversity of social welfare and rehabilitation sciences0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 50 years(—)
性别
All

入选标准

  • Diagnosis of schizophrenia based on DSM-5
  • Age between 18-50
  • At least 2 years have been passed since the diagnosis
  • Have been stable with risperidone treatment for at least 2 months

排除标准

  • Head trauma
  • History of shock therapy during the last three months
  • Neurosurgery
  • Diagnosis of acute or chronic systemic disease
  • Alcohol or drug addiction in the last 6 months
  • Suicidal ideation
  • Pregnancy or lactation
  • IQ less than 70 based on the diagnosis of a psychiatrist
  • ECT during recent two months
  • Taking oral antipsychotics, excluding risperidone, in the past week or long-acting antipsychotics in the past month
  • The presence of another diagnosis in axis II
  • History of heart disease
  • Family history of heart disease and heart failure
  • Taking insulin
  • Liver disorders
  • The development of a drug complication that requires emergency action: edema, congestive heart failure, heart pain and changes in the basic ECG, hypoglycemia, the occurrence of malignant neuroleptic syndrome

研究者

发起方
niversity of social welfare and rehabilitation sciences

相似试验

The effect of Rosiglitazone on negative symptoms in... | 临床试验